• Subscribe
  • Newsfeed
  • About
  • Jobs
AI Search
Announce News

Atelerix: Venture Capital Funding History

Atelerix

To add a bio or update company history, please click update information.

News from Atelerix

    Atelerix lands £750k from ACF Investors and o2h ventures to revolutionise biological transportAtelerix lands £750k from ACF Investors and o2h ventures to revolutionise biological transport
    Atelerix
    28 Jan 2025

    Atelerix lands £750k from ACF Investors and o2h ventures to revolutionise biological transport

    Atelerix develops hydrogel technology that allows biological samples to be stored and shipped at ambient temperatures while maintaining cell viability.

Atelerix
  • Life Sciences
  • Newcastle, United Kingdom
  • £750k
  • atelerix.co.uk
  • Update Information

More venture news

  • Oyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases
    Oyster Therapeutics
    13 Nov 2026

    Oyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases

    Series ALife Sciences
  • Neobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours
    Neobe Therapeutics
    10 Nov 2026

    Neobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours

    SeedLife Sciences
  • PhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases
    PhaSER Biomedical
    9 Nov 2026

    PhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases

    GrantLife Sciences

Sign-up to our newsletter

The UK Weekly email covers every VC round from last week, firms that are hiring, and much more

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn

Announce

  • Share your story

General

  • Read the latest
  • About Soapbox

Information not up to date?

Get in touch

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn